Prot #AL3818-US-004: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Project: Research project

StatusActive
Effective start/end date9/20/199/20/22

Funding

  • Advenchen Laboratories, LLC (Prot #AL3818-US-004)